Citius Pharmaceuticals Triumphs, Achieving Nasdaq Compliance Again
Citius Pharmaceuticals Celebrates Nasdaq Compliance Restoration
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) has exciting news to share, as the company has successfully regained compliance with the Nasdaq's minimum bid price requirement. This announcement marks a significant milestone for Citius Pharma, affirming its strong position in the biopharmaceutical industry.
Details of the Compliance Notification
Recently, Citius Pharmaceuticals received an official notification from Nasdaq confirming that for a period of 10 consecutive trading days, the closing bid price of its common stock held above $1.00 per share. Specifically, this period was between June 20 and July 3, effectively leading to the cancellation of a previously scheduled hearing with the Nasdaq Hearing Panel.
CEO's Perspective on Compliance
Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, expressed his satisfaction with this achievement, stating, "We are pleased to have regained compliance with Nasdaq's minimum bid price requirement. This reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders." The implication of this sentiment resonates throughout the company, showcasing a commitment to growth.
Understanding Citius Pharmaceuticals' Mission
Citius Pharmaceuticals has earned its reputation as a biopharmaceutical company focused on developing and commercializing first-in-class critical care products. One of the most notable advancements is the FDA's approval of LYMPHIR, which is a targeted immunotherapy primarily indicated for the treatment of cutaneous T-cell lymphoma. This approval is a testament to the company’s innovative approach to patient care.
Current Product Pipeline Initiatives
In addition to LYMPHIR, Citius Pharma has a promising late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution aimed at salvaging catheters used in patients suffering from catheter-related bloodstream infections, along with CITI-002 (Halo-Lido), a topical formulation designed to relieve hemorrhoid discomfort. The company completed both pivotal Phase 3 and Phase 2b clinical trials successfully in 2023, indicating strong potential for these products.
Ongoing FDA Engagement
Citius Pharmaceuticals actively engages with the FDA to outline the next steps for both Mino-Lok and CITI-002. This level of communication with regulatory authorities is crucial for ensuring timely progress in the commercialization of their products, thus allowing them to better serve patients and health care providers alike. It showcases the company's commitment to driving meaningful advancement in healthcare solutions.
Overview of Company Ownership and Structure
An impressive aspect of Citius Pharmaceuticals is its ownership structure—92% of Citius Oncology lies within its portfolio, indicating a robust foundation for future endeavors. This strategic component allows for broader opportunities in cancer-related therapies, enhancing the company's footprint in the biopharmaceutical landscape.
Investor and Media Contacts
For investor relations, reach out to Ilanit Allen, VP of Corporate Communications & Investor Relations at Citius Pharmaceuticals. She is available at ir@citiuspharma.com or you can contact her directly at 908-967-6677 ext. 113. For media inquiries, Greg Salsburg at STiR Communications can be reached via email at Greg@STiR-communications.com or the same phone number as above.
Frequently Asked Questions
What recent compliance milestone did Citius Pharmaceuticals achieve?
Citius Pharmaceuticals regained compliance with Nasdaq's minimum bid price requirement, surpassing a $1.00 share price for ten consecutive days.
Who is the CEO of Citius Pharmaceuticals, and what was their comment on this achievement?
Leonard Mazur is the CEO, and he noted that this compliance reflects the company's dedication to patient care and shareholder value.
What significant product did Citius Pharmaceuticals recently receive FDA approval for?
They received FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma.
How does Citius Pharmaceuticals engage with the FDA concerning its pipeline products?
Citius engages actively with the FDA to discuss next steps for their pivotal clinical trials and commercialization efforts.
What other products are in Citius Pharmaceuticals' pipeline?
Other products include Mino-Lok®, designed to salvage catheters, and Halo-Lido, a topical solution for hemorrhoid relief.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
